• Adams, J., Behnke, M., Chen, S., Cruickshank, A.A., Dick, L.R., Grenier, L., Klunder, J.M., Ma, Y.T., Plamondon, L. & Stein, R.L. (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorganic and Medicinal Chemistry Letters, 8, 333338.
  • Aghajanian, C., Soignet, S., Dizon, D.S., Pien, C.S., Adams, J., Elliott, P.J., Sabbatini, P., Miller, V., Hensley, M.L., Pezzulli, S., Canales, C., Daud, A. & Spriggs, D.R. (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clinical Cancer Research, 8, 25052511.
  • Alexanian, R. & Dimopoulos, M. (1994) The treatment of multiple myeloma. New England Journal of Medicine, 330, 484489.
  • Bladé, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 11151123.
  • Desterro, J.M., Rodriguez, M.S. & Hay, R.T. (2000) Regulation of transcription factors by protein degradation. Cellular and Molecular Life Sciences, 57, 12071219.
  • Dulic, V., Kaufmann, W.K., Wilson, S.J., Tlsty, T.D., Lees, E., Harper, J.W., Elledge, S.J. & Reed, S.I. (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76, 10131023.
  • Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 30713076.
  • King, R.W., Deshaies, R.J., Peters, J.M. & Kirschner, M.W. (1996) How proteolysis drives the cell cycle. Science, 274, 16521659.
  • LeBlanc, R., Catley, L.P., Hideshima, T., Lentzsch, S., Mitsiades, C.S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C.S., Adams, J., Gupta, D., Richardson, P.G., Munshi, N.C. & Anderson, K.C. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research, 62, 49965000.
  • Orlowski, R.Z. (1999) The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death and Differentiation, 6, 303313.
  • Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D.L., Elliott, P.J., Pien, C.S., Guerciolini, R., Anderson, J.K., Depcik-Smith, N.D., Bhagat, R., Lehman, M.J., Novick, S.C., O'Connor, O.A. & Soignet, S.L. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology, 20, 44204427.
  • Rajkumar, S.V., Gertz, M.A., Kyle, R.A. & Greipp, P.R. (2002) Current therapy for multiple myeloma. Mayo Clinic Proceedings, 77, 813822.
  • Read, M.A., Neish, A.S., Luscinskas, F.W., Palombella, V.J., Maniatis, T. & Collins, T. (1995) The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity, 2, 493506.
  • Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. Srkalovic & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 26092617.
  • Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 15651571.
  • Strasser, K. & Ludwig, H. (2002) Thalidomide treatment in multiple myeloma. Blood Reviews, 16, 207215.